Schizophrenia
📧 Sign up to get email alerts when something new happens for Schizophrenia.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2009-07-19FDA Approved: RISPERDAL CONSTA — Supplemental Application (Janssen Pharmaceuticals, Inc.)
FDA approved a supplemental application for Risperdal Consta, the long-acting injectable form of risperidone, submitted by Janssen Pharmaceu…
-
FDA approval · 2009-07-19FDA Approved: GEODON — Supplemental Application (Viatris Specialty LLC)
The FDA approved a supplemental application for Geodon (ziprasidone) submitted by Viatris Specialty LLC.
-
FDA approval · 2009-07-19FDA Approved: HALOPERIDOL DECANOATE — Supplemental Application (Patriot Pharmaceuticals LLC)
FDA approved a supplemental application for haloperidol decanoate submitted by Patriot Pharmaceuticals LLC. Haloperidol decanoate is a long-…
-
FDA approval · 2009-07-16FDA Approved: HALOPERIDOL — Supplemental Application (Mylan Pharmaceuticals Inc.)
The FDA approved a supplemental application for HALOPERIDOL by Mylan Pharmaceuticals Inc.
-
CLINICAL_TRIALS trial_result · 2009-07-13Clinical Trial Update: The Study of Atypical Antipsychotics-induced Metabolic Disturbances
A completed clinical trial evaluating metabolic disturbances linked to atypical antipsychotics in schizophrenia.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2009-06-29Clinical Trial Update: A Repeat Dose Study With GSK1018921 to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics in Healthy Volunteers and Patients With Schizophrenia and to Evaluate Its Effect on PK of Midazolam. [Phase 1]
A Phase 1 repeat-dose study of GSK1018921 in healthy volunteers and schizophrenia patients to assess safety, tolerability, pharmacokinetics …
-
CLINICAL_TRIALS trial_result · 2009-06-24Clinical Trial Update: Identification and Treatment of the Liability to Develop Schizophrenia [Phase 4]
Phase 4 update from Central South University focusing on identifying individuals at risk for schizophrenia and evaluating preventive treatme…
-
FDA approval · 2009-06-17FDA Approved: RISPERIDONE — Original Application (Amneal Pharmaceuticals NY LLC)
The FDA approved Amneal Pharmaceuticals NY LLC's original ANDA for risperidone, authorizing a generic version of the antipsychotic.
-
CLINICAL_TRIALS trial_result · 2009-06-16Clinical Trial Update: Seroquel (Quetiapine Fumarate) InPractice Evaluation Programme
This ClinicalTrials.gov entry shows that AstraZeneca's Seroquel (quetiapine fumarate) InPractice Evaluation Programme for schizophrenia has …
-
CLINICAL_TRIALS research · 2009-06-12Clinical Trial Update: Association of Multiple Genetic Polymorphisms With Clozapine-Associated Metabolic Change in Schizophrenia
This clinical trial update investigates whether multiple genetic polymorphisms influence metabolic changes seen in schizophrenia patients tr…
-
CLINICAL_TRIALS trial_result · 2009-06-12Clinical Trial Update: Recovery Guide Intervention for Recurrent Psychiatric Hospitalization [NA]
This clinical trial evaluating a Recovery Guide Intervention for recurrent psychiatric hospitalization has completed, sponsored by Yale Univ…
-
CLINICAL_TRIALS trial_result · 2009-06-12Clinical Trial Update: Effect on Metabolic Parameters of Abilify in SPR
This clinical trial update evaluates the effects of Abilify (aripiprazole) on metabolic parameters in patients with schizophrenia and metabo…
-
CLINICAL_TRIALS research · 2009-06-12Clinical Trial Update: Prevalence of the Metabolic Syndrome in SPR Taking Antipsychotics
This clinical trial update assesses the prevalence of metabolic syndrome among individuals taking antipsychotics, including those with schiz…
-
CLINICAL_TRIALS trial_result · 2009-06-11Clinical Trial Update: Rapid Dose Escalation of Quetiapine Versus Conventional Escalation in Acute Schizophrenic Patients [Phase 2]
A Phase 2 trial comparing rapid dose escalation of quetiapine versus conventional escalation in acute schizophrenia has completed.
-
CLINICAL_TRIALS trial_result · 2009-06-11Clinical Trial Update: Safety and Efficacy of Seroquel in First Episode Schizophrenia [Phase 4]
Phase 4 study evaluating the safety and efficacy of quetiapine (Seroquel) in patients experiencing their first episode of schizophrenia. The…
-
CLINICAL_TRIALS trial_result · 2009-06-11Clinical Trial Update: Effect of Quetiapine on Negative Symptoms and Cognition [Phase 3]
A Phase 3 clinical trial evaluating quetiapine for negative symptoms and cognition in schizophrenia has completed. The entry notes the study…
-
FDA approval · 2009-06-04FDA Approved: LOXAPINE — Supplemental Application (Actavis Pharma, Inc.)
FDA approves a supplemental application for LOXAPINE (loxapine) by Actavis Pharma, Inc., resulting in an updated marketing authorization for…
-
FDA approval · 2009-06-04FDA Approved: LOXAPINE — Supplemental Application (Actavis Pharma, Inc.)
FDA approved a supplemental application for LOXAPINE (loxapine) by Actavis Pharma, Inc., resulting in changes to its labeling. The approval …
-
CLINICAL_TRIALS trial_result · 2009-06-02Clinical Trial Update: Comparing the Effect of Under the Tongue Olanzapine Versus Swallowed Olanzapine on Body Mass Index (A Ratio of Weight to Height) [Phase 4]
This Phase 4 trial compared under-the-tongue olanzapine to swallowed olanzapine to evaluate effects on body mass index in patients with schi…
-
FDA approval · 2009-05-27FDA Approved: LOXAPINE — Supplemental Application (Actavis Pharma, Inc.)
FDA approved a supplemental application for LOXAPINE (loxapine) from Actavis Pharma, Inc.
-
FDA approval · 2009-05-27FDA Approved: LOXAPINE — Supplemental Application (Actavis Pharma, Inc.)
FDA approved a supplemental application for LOXAPINE (loxapine) from Actavis Pharma, Inc., under ANDA072205. This action represents an appro…
-
FDA approval · 2009-05-22FDA Approved: TRIFLUOPERAZINE HYDROCHLORIDE — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approved a supplemental application for trifluoperazine hydrochloride from Mylan Pharmaceuticals Inc., approving the generic product und…
-
FDA approval · 2009-05-22FDA Approved: FLUPHENAZINE DECANOATE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA approved a supplemental application for Fluphenazine Decanoate from Hikma Pharmaceuticals USA Inc. The action pertains to a supplemental…
-
CLINICAL_TRIALS trial_result · 2009-05-19Clinical Trial Update: Nicotine Replacement Therapy for Smoking Cessation in Schizophrenia [Phase 4]
Phase 4 trial assessing nicotine replacement therapy for smoking cessation in people with schizophrenia or schizoaffective disorder has comp…
-
CLINICAL_TRIALS trial_result · 2009-05-19Clinical Trial Update: Antipsychotic Polypharmacy in Schizophrenia [NA]
This entry provides an update on a clinical trial studying antipsychotic polypharmacy in schizophrenia. The study status is listed as comple…